MA52361A - Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées - Google Patents

Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées

Info

Publication number
MA52361A
MA52361A MA052361A MA52361A MA52361A MA 52361 A MA52361 A MA 52361A MA 052361 A MA052361 A MA 052361A MA 52361 A MA52361 A MA 52361A MA 52361 A MA52361 A MA 52361A
Authority
MA
Morocco
Prior art keywords
peptide
tyrosine
glp
glucagon
cyclic
Prior art date
Application number
MA052361A
Other languages
English (en)
Inventor
Raul Camacho
Martin A Case
Ellen Chi
Suzanne Edavettal
Wilson Edwards
Lisa Norquay
Mark J Wall
Rui Zhang
Yue-Mei Zhang
Songmao Zheng
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA52361A publication Critical patent/MA52361A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA052361A 2018-04-25 2019-04-24 Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées MA52361A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662313P 2018-04-25 2018-04-25
US2018029284 2018-04-25

Publications (1)

Publication Number Publication Date
MA52361A true MA52361A (fr) 2021-03-03

Family

ID=66676857

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052361A MA52361A (fr) 2018-04-25 2019-04-24 Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées

Country Status (23)

Country Link
EP (1) EP3784692A1 (fr)
JP (1) JP2021522258A (fr)
KR (1) KR20210005674A (fr)
CN (1) CN112004822A (fr)
AU (2) AU2019259790B2 (fr)
BR (1) BR112020021562A2 (fr)
CA (1) CA3096792A1 (fr)
CL (1) CL2020002718A1 (fr)
CO (1) CO2020013221A2 (fr)
CR (1) CR20200487A (fr)
DO (1) DOP2020000192A (fr)
EC (1) ECSP20067968A (fr)
IL (1) IL278197A (fr)
JO (1) JOP20200265A1 (fr)
MA (1) MA52361A (fr)
MX (1) MX2020011293A (fr)
NI (1) NI202000071A (fr)
PE (1) PE20211457A1 (fr)
PH (1) PH12020551659A1 (fr)
SA (1) SA520420401B1 (fr)
SG (1) SG11202009844SA (fr)
UY (1) UY38200A (fr)
WO (1) WO2019207505A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
CA3241537A1 (fr) * 2021-12-31 2023-07-06 Jiangyu YAN Proteine de fusion de glp-1 et de gdf15 et son utilisation
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN117327200B (zh) * 2023-11-28 2024-02-09 西宝生物科技（上海）股份有限公司 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961000B (zh) * 2004-02-11 2011-05-04 安米林药品公司 具有可选择特性的杂合多肽
WO2005089789A2 (fr) * 2004-03-17 2005-09-29 7Tm Pharma A/S Agonistes selectifs du recepteur y2 utilises dans des interventions therapeutiques
KR20070094909A (ko) * 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
US20090175795A1 (en) * 2005-07-29 2009-07-09 Amprotein Corporation Chimeric therapeutic agents
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
JP5399244B2 (ja) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
CN102666586A (zh) * 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
CA3003465A1 (fr) * 2015-10-28 2017-05-04 Krishna Kumar Nouveaux polypeptides presentant une meilleure stabilite et procedes de preparation et d'utilisation associes
JOP20190097A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها

Also Published As

Publication number Publication date
AU2019259790B2 (en) 2023-08-31
SG11202009844SA (en) 2020-11-27
PH12020551659A1 (en) 2021-07-26
UY38200A (es) 2019-10-31
TW202014433A (zh) 2020-04-16
JP2021522258A (ja) 2021-08-30
SA520420401B1 (ar) 2023-01-26
CN112004822A (zh) 2020-11-27
BR112020021562A2 (pt) 2021-03-02
MX2020011293A (es) 2020-11-13
ECSP20067968A (es) 2020-11-30
CA3096792A1 (fr) 2019-10-31
CL2020002718A1 (es) 2021-01-29
WO2019207505A1 (fr) 2019-10-31
PE20211457A1 (es) 2021-08-05
KR20210005674A (ko) 2021-01-14
EP3784692A1 (fr) 2021-03-03
CR20200487A (es) 2021-03-11
AU2019259790A1 (en) 2020-10-22
JOP20200265A1 (ar) 2020-10-21
IL278197A (en) 2020-11-30
AU2023274117A1 (en) 2023-12-21
DOP2020000192A (es) 2021-04-30
CO2020013221A2 (es) 2020-11-10
NI202000071A (es) 2021-01-21

Similar Documents

Publication Publication Date Title
MA52361A (fr) Conjugués peptidiques cycliques tyrosine-tyrosine couplés à un peptide de fusion du peptide 1 apparenté au glucagon (glp-1) et utilisations associées
DK3806855T5 (da) GLP-1-receptoragonister og anvendelser deraf
DK3806955T3 (da) GLP-1-receptoragonister og anvendelser deraf
AU2019410856B2 (en) Reality capture with a laser scanner and a camera
FR3053530B1 (fr) Dispositif optoelectronique a pixels a contraste et luminance ameliores
DK3849614T3 (da) Interleukin-2-polypeptidkonjugater og anvendelser deraf
DK3505914T3 (da) Billedsensorstruktur, fremgangsmåde til dannelse af en sådan billedsensorstruktur og anvendelse af en sådan billedsensorstruktur i et biologisk assay
DK3446613T3 (da) Moppespand til rengøring og vridning af en flad moppe
DK3720279T3 (da) Mus med et modificeret immunoglobulin-Lambda-letkæde og anvendelser deraf
EP3190782A3 (fr) Caméra d'action
MA55069A (fr) Nouvelles protéines de fusion spécifique à cd137 et gpc3
FR2889969B1 (fr) Simulateur de chutes libres apte a presenter un environnement visuel simule
MA53809A (fr) Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
DK3574150T3 (da) Samling, der omfatter et første og et andet afsnit og en fiksering
MA50474A (fr) Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1
MA51748A (fr) Dispositif de detection tactile avec interface tactile en materiau composite
DK3790548T3 (da) Fremgangsmåder til forbedring af biotilgængeligheden og eksponeringen af en åbner af spændingsstyret kaliumkanal
SG11202012074VA (en) Antibodies comprising a polypeptide inserted in framework 3 region
MA47598A (fr) Vitrage a contrainte d'extension reduite
MA54811A (fr) Ensembles vitres feuilletées à élément fonctionnel électro-optique
DK3519635T3 (da) Pæleføring omfattende en basisramme og et føringselement
EP3979341A4 (fr) Élément électroluminescent ayant une électrode en porte-à-faux, panneau d'affichage le comprenant, et dispositif d'affichage
DK3530868T3 (da) Endestykke til en kantskinne på en solskærm og solsejl
TWI847981B (zh) 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
FR3034304A1 (fr) Bracelet hemostatique